Showing results (211-220 of 330) with videos related to
Sort By:
Pageof 33
Journal of Medical Virology|March 6, 2026
Changes in the Liver Fibrosis of Patients Who Develop Hepatocellular Carcinoma After a Sustained Virologic Response to Hepatitis C Virus InfectionHidenori Toyoda, Akito Nozaki, Atsushi Hiraoka, et al.Cancers|January 30, 2020
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular CarcinomaMakoto Chuma, Haruki Uojima, Kazushi Numata, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 18, 2016
Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in PatientsSarah Berhane, Hidenori Toyoda, Toshifumi Tada, et al.Oncology|February 26, 2020
Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 2, 2026
Diagnostic Impact of Two-Dimensional Shear Wave Elastography for Liver Fibrosis: A Multicenter Retrospective StudyTakashi Nishimura, Toshifumi Tada, Yasuaki Suzuki, et al.Liver Cancer|February 20, 2020
Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with LenvatinibAtsushi Hiraoka, Takashi Kumada, Shinya Fukunishi, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 11, 2026
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular CarcinomaKazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, et al.Oncology|July 16, 2019
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.Journal of Clinical Medicine|March 27, 2025
Association Between Laboratory Values and Covert Hepatic Encephalopathy in Patients with Liver Cirrhosis: A Multicenter, Retrospective StudyKaori Koyano, Masanori Atsukawa, Akihito Tsubota, et al.Journal of Gastroenterology|March 7, 2025
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept studyTomoko Aoki, Masatoshi Kudo, Naoshi Nishida, et al.Pageof 33